370 related articles for article (PubMed ID: 34252168)
1. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.
Prabhakara C; Godbole R; Sil P; Jahnavi S; Gulzar SE; van Zanten TS; Sheth D; Subhash N; Chandra A; Shivaraj A; Panikulam P; U I; Nuthakki VK; Puthiyapurayil TP; Ahmed R; Najar AH; Lingamallu SM; Das S; Mahajan B; Vemula P; Bharate SB; Singh PP; Vishwakarma R; Guha A; Sundaramurthy V; Mayor S
PLoS Pathog; 2021 Jul; 17(7):e1009706. PubMed ID: 34252168
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.
Shang C; Zhuang X; Zhang H; Li Y; Zhu Y; Lu J; Ge C; Cong J; Li T; Tian M; Jin N; Li X
Virol J; 2021 Feb; 18(1):46. PubMed ID: 33639976
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
4. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis.
Bayati A; Kumar R; Francis V; McPherson PS
J Biol Chem; 2021; 296():100306. PubMed ID: 33476648
[TBL] [Abstract][Full Text] [Related]
7. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling.
Karthika T; Joseph J; Das VRA; Nair N; Charulekha P; Roji MD; Raj VS
Cells; 2021 Jul; 10(7):. PubMed ID: 34359983
[TBL] [Abstract][Full Text] [Related]
9. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
12. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S
Elife; 2020 Oct; 9():. PubMed ID: 33103998
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
[TBL] [Abstract][Full Text] [Related]
15. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
16. ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin.
Partridge LJ; Urwin L; Nicklin MJH; James DC; Green LR; Monk PN
Cells; 2021 Jun; 10(6):. PubMed ID: 34200372
[TBL] [Abstract][Full Text] [Related]
17. Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infection.
Vanslambrouck JM; Neil JA; Rudraraju R; Mah S; Tan KS; Groenewegen E; Forbes TA; Karavendzas K; Elliott DA; Porrello ER; Subbarao K; Little MH
J Virol; 2024 Mar; 98(3):e0180223. PubMed ID: 38334329
[TBL] [Abstract][Full Text] [Related]
18. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2.
Zhao H; To KKW; Lam H; Zhou X; Chan JF; Peng Z; Lee ACY; Cai J; Chan WM; Ip JD; Chan CC; Yeung ML; Zhang AJ; Chu AWH; Jiang S; Yuen KY
Nat Commun; 2021 Mar; 12(1):1517. PubMed ID: 33750821
[TBL] [Abstract][Full Text] [Related]
19. Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses.
Galindo I; Garaigorta U; Lasala F; Cuesta-Geijo MA; Bueno P; Gil C; Delgado R; Gastaminza P; Alonso C
Antiviral Res; 2021 Feb; 186():104990. PubMed ID: 33249093
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
